Gapping up
In reaction to earnings/guidance:
- PRGS +0.7% (guidance update)
Other news:
- ALBO +90% (phase 3 trial meets both primary endpoints for Odevixibat in PFIC)
- NKLA +35% (Nikola Corporation and and General Motors (GM) form strategic partnership; Nikola badger to be engineered and manufactured by General Motors)
- SPRO +23.1% (announces topline results from ADAPT-PO)
- KMDA +18.6% (announces completion of enrollment and initial interim results from its ongoing Phase 1/2 open-label clinical trial in Israel of the company's anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin product as a potential treatment for coronavirus disease)
- VRNA +9.8% (initiates pilot study with pMDI Ensifentrine in US patients hospitalized with COVID-19)
- VXX +8.7% (trading higher with futures indicated lower)
- BYSI +8.5% (receives Breakthrough Therapy Designation for the chemotherapy-induced neutropenia indication from both the FDA and China's Center for Drug Evaluation of the National Medical Products Administration)
- GRFS +4% (to acquire Alkahest for $146 mln)
- OCUL +3.5% (received a letter from the FDA closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant)
- CHDN +2.9% (following Derby weekend)
- LMNL +2.4% (announces resubmission of biologics license application to FDA for Ryplazim for treatment of congenital plasminogen deficiency)
- BPMC +2.3% (receives FDA approval for GAVRETO)
- ETSY +1.9% (will move to the S&P 500)
- AZN +1.7% (New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress 2020)
Analyst comments:
- CWH +1.8% (upgraded to Overweight from Neutral at JP Morgan)
- PLAY +1.7% (upgraded to Buy from Hold at Deutsche Bank)
- DIS +0.9% (upgraded to Buy from Hold at Deutsche Bank)
- AA +0.8% (upgraded to Buy from Neutral at BofA Securities)